



London and South East Sarcoma Network
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site
Specialised MDTs
Urology

Background

This guidance is to provide direction for the management of patients with sarcomas that may present through urology cancer services and to define the relationship that should exist with the specialist sarcoma MDT. This guidance refers to the care of patients in the London and South East Sarcoma Network and therefore recognises that specialist services for soft tissue sarcomas are provided by the Sarcoma Unit at The Royal Marsden Hospital and the London Sarcoma Service provided through joint working of UCLH and RNOH.

Principals

This guidance is being developed in accordance with the relevant measures in the Manual for Cancer Services: Sarcoma Measures and the Manual for Cancer Services: Urology Measures. They are also written in accordance with the LSESN referral guidelines (see www.lsesn.nhs.uk) and the LSESN Patient Management Policy.

1) Notification

All sarcoma patients presenting to a local or specialist Urology MDT should be notified to the sarcoma MDT nominated in the local network urology cancer operational policy.

2) Review by Sarcoma MDT

a) Pathology

All urology sarcomas will have pathology review undertaken by the nominated specialist sarcoma pathology service (for details see MDT operational policies).

b) Management

Management of all new soft tissue sarcomas will be referred to the sarcoma MDT. Early referral from the time of suspicion or biopsy is recommended.

3) Site of Definitive Treatment

Discussion between MDT's will take place to determine the appropriate hospital for definitive excision. Initial surgical treatment may be undertaken by the local or specialist urology team. It is preferred that complex surgery, i.e. multivisceral resection or operations requiring complex reconstructive procedures, and second operations take place at a sarcoma centre.

Chemotherapy and radiotherapy will be undertaken by designated practitioners as agreed by the SAG.

4) Recurrence


All recurrent urology sarcomas will be discussed and reviewed by the sarcoma MDT.

FILE NAME	SHARED CARE PATHWAY FOR SOFT TISSUE SARCOMAS PRESENTING TO SITE SPECIALISED MDTs: UROLOGY	AUTHOR	LSESN SAG	ISSUE NO	1	PAGE NO	1 OF 3	DATE	OCTOBER 2011
-----------	---	--------	-----------	----------	---	---------	--------	------	--------------



	Role and Responsibility	
	Specialist/Local Urology MDT/Clinic	Sarcoma MDT/Clinic
Presentation	Assess new cases of suspected urology cancer Notify Sarcoma MDT of all new cases of urology sarcoma	
Diagnosis	Refer all cases of urology sarcoma for pathology review Refer all new cases of urology sarcoma for review by sarcoma MDT	Review pathology of all new cases of urology sarcoma Clinical review of all new cases
Treatment	Initial surgery	Complex surgery and second operations All chemotherapy All radiotherapy
Follow up	Follow up according to agreed Urology MDT guidelines	Follow up in accordance with sarcoma follow up guidelines of all patients treated by the sarcoma MDT

Pathway Summary:



LSS MDT Coordinator Contact details:
Ucl-tr.LondonSarcomaService@nhs.net
 Tel: 020 3447 4821

RMH MDT Coordinator Contact details:
Joe.pace@nhs.net
 Tel: 020 7811 8078

* Follow Up according to agreed urology MDT guidelines and LSESN sarcoma follow-up guidelines (for those patients treated by sarcoma MDT)

FILE NAME	SHARED CARE PATHWAY FOR SOFT TISSUE SARCOMAS PRESENTING TO SITE SPECIALISED MDTs: UROLOGY	AUTHOR	LSESN SAG	ISSUE NO	1	PAGE NO	3 OF 3	DATE	OCTOBER 2011
-----------	---	--------	-----------	----------	---	---------	--------	------	--------------